Earnings Releases·Oct 28, 2026, 6:57 AM ET

Labcorp — Q3 2026 Earnings Summary

Total revenue reached $3.81 billion (up 6.9% YoY) and adjusted EPS rose 14.5% to $4.78, driven by volume growth and price/mix improvements.
Management raised full-year 2026 enterprise revenue guidance to 5.9%–6.7% and adjusted EPS guidance to $18.30–$18.70, while maintaining free cash flow guidance at $1.24 billion–$1.36 billion.
The company executed significant capital allocation, investing $255.5 million in acquisitions (including MLM Medical Labs) and announcing agreements for BioReference, Myriad Genetics, and Millennium Health assets, alongside a new $0.72 quarterly dividend.
Strategic momentum continues with FDA approvals for the PGDx elio® test and Elecsys® pTau-217 blood test, plus expanded partnerships for HPV and bladder cancer testing, supporting a backlog of $8.92 billion in the Biopharma segment.